Imatinib Mesylate Tablet, Film Coated
Product Images NDC 31722-296

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 31722-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib100mg90scontainer (Imatinib100mg90scontainer)

Imatinib Mesylate Tablets 100 mg film-coated tablets packaging label from Camber Pharmaceuticals, Inc. The label indicates a package of 90 tablets, with storage instructions, dosage note referring to prescribing information, and a U.S. contact number. Manufacturing and labeling details include the NDC 31722-296-90 and mention of Hetero Labs Limited, India as the producer.*

FDA Label Image

Imatinib400mg30scontainer (Imatinib400mg30scontainer)

Label for Imatinib Mesylate Tablets 400 mg by Camber Pharmaceuticals, Inc. The label shows 30 film-coated tablets, with NDC 31722-297-30. It includes storage instructions, a U.S. contact number, manufacturer information, and a barcode. The label notes the dosage strength as 400 mg of imatinib free base per tablet.*

FDA Label Image

Imatinibcamberlogo (Imatinibcamberlogo)

FDA Label Image

Imatinibfigure1 (Imatinibfigure1)

A line chart depicting the percentage of patients without progression over time in months since randomization. It compares two treatment arms: Imatinib Mesylate and IFN+Ara-C. The y-axis shows % without progression from 0 to 100, and the x-axis shows time in months up to 72. The chart includes hazard ratio and patient numbers for each arm, illustrating progression-free survival over approximately six years.*

FDA Label Image

Imatinibfigure2 (Imatinibfigure2)

A line graph comparing the percentage of patients without progression to AP or BC over time in months since randomization between two groups: Imatinib Mesylate arm (solid line) and IFN+Ara-C arm (dashed line). The chart includes patient counts, hazard ratio, confidence interval, and p-value for statistical significance.*

FDA Label Image

Imatinibfigure3 (Imatinibfigure3)

A survival curve chart depicting the probability of being alive and recurrence-free over survival time in months. The chart compares two groups: Imatinib 400 mg (solid line) and placebo (dashed line) with censored data points indicated by circles and plus signs. The x-axis shows survival time in months up to 108, and the y-axis shows probability from 0 to 1. The number of patients at risk for both groups is listed below the x-axis at various time points.*

FDA Label Image

Imatinibfigure4 (Imatinibfigure4)

A Kaplan-Meier survival curve chart showing the probability of recurrence-free survival over a survival time in months. Two groups are compared: Imatinib treatment at 12 months represented by a solid line and at 36 months by a dashed line. The chart includes event and censored data points and a table summarizing the number at risk and events over time.*

FDA Label Image

Imatinibfigure5 (Imatinibfigure5)

A Kaplan-Meier survival curve chart showing the probability of overall survival over time in months. Two treatment groups are compared: Imatinib 12 months (solid line) and Imatinib 36 months (dashed line), with censored observations marked by vertical ticks. The chart includes statistical data such as a P-value of 0.0187, hazard ratio of 0.45 with 95% confidence interval, and tables of numbers at risk, events, and censored counts below the x-axis.*

FDA Label Image

Imatinibstructure (Imatinibstructure)

Chemical structure of imatinib mesylate showing its molecular framework with various rings and functional groups, including a mesylate (CH3SO3H) component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.